Join
Live feed
·
PRReleasevia Quantisnow
Krystal Biotech Inc. logo

Krystal Biotech Announces United Kingdom MHRA Approval of VYJUVEK® for the Treatment of Dystrophic Epidermolysis Bullosa

ByQuantisnow·Wall Street's wire, on your screen.
KRYS· Krystal Biotech Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track KRYS (Krystal Biotech Inc.) and more on Quantisnow.